Format

Send to

Choose Destination
Eur J Nutr. 2019 Apr;58(3):1203-1211. doi: 10.1007/s00394-018-1638-9. Epub 2018 Feb 21.

Modulation by hydroxytyrosol of oxidative stress and antitumor activities of paclitaxel in breast cancer.

Author information

1
"José Mataix" Institute of Nutrition and Food Technology, Biomedical Research Centre, Health Sciences Technological Park, University of Granada, 18016, Armilla, Granada, Spain.
2
Department of Biochemistry and Molecular Biology II, University of Granada, 18016, Armilla, Granada, Spain.
3
Department of Pathological Anatomy, Hospital Complex of Jaén, Jaén, Spain.
4
Department of Physiology, University of Granada, Granada, Spain.
5
Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA.
6
Oncology Service, Jaen City Hospital, Jaén, Spain.
7
Methodist Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
8
"José Mataix" Institute of Nutrition and Food Technology, Biomedical Research Centre, Health Sciences Technological Park, University of Granada, 18016, Armilla, Granada, Spain. mramirez@ugr.es.
9
Department of Biochemistry and Molecular Biology II, University of Granada, 18016, Armilla, Granada, Spain. mramirez@ugr.es.

Abstract

PURPOSE:

The main objective of this study was to test the therapeutic potential of hydroxytyrosol and its combination with paclitaxel in breast cancer on oxidative stress status.

METHODS:

Impact on proliferation rates of different chemotherapy administration patterns was assayed in MCF-7 and MDA-MB-231 breast cancer cell lines. Breast tumor-bearing rats were randomly assigned to Control, Hydroxytyrosol, Paclitaxel and Paclitaxel plus hydroxytyrosol groups, for 6 weeks. Tumor volume, cell proliferation and several systemic oxidative stress parameters were measured. Anti-proliferative activity in vitro experiments was correlated with in vivo experiments.

RESULTS:

Combination group did significantly reduce tumor volume when compared with paclitaxel alone. Additionally, the combination improved the antioxidant status without compromising the antitumor activity of standard chemotherapy.

CONCLUSION:

These findings reveal for the first time that hydroxytyrosol is an active partner in combined therapies with paclitaxel against breast cancer. Combination with hydroxytyrosol would also ensure a less oxidative impact of chemotherapeutic drugs that could potentially improve patient wellness.

KEYWORDS:

Breast cancer; Cell proliferation; Hydroxytyrosol; Multimodal treatment and paclitaxel; Oxidative stress

PMID:
29468462
DOI:
10.1007/s00394-018-1638-9

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center